Sinus Microbiota Analysis and Probiotic Treatment for Chronic Rhinosinusitis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Chronic Rhinosinusitis (CRS) is poorly understood in terms of microbiology, with existing culture-based approaches underestimating the diversity of sinus microbiota, and current treatments often fail to address the underlying microbiome imbalance, leading to persistent inflammation and infection.
Innovation Solution
A culture-independent analysis identifies specific bacteria such as Lactobacillus sakei as protective species and Corynebacterium tuberculostearicum as pathogenic, leading to the development of probiotics and pharmaceutical compositions to improve sinus microbiota diversity and reduce pathogenic bacteria, administered nasally to treat sinusitis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If culture-based approaches are used to analyze sinus microbiota, then the analysis method is simple and familiar, but the diversity of species present is underestimated
Solution Approach 1:
The patent replaces traditional culture-based mechanical/biological methods with molecular biology techniques (PCR, sequencing) to detect and analyze sinus microbiota. This substitution enables accurate identification of bacterial diversity without relying on culture growth, thereby resolving the contradiction between measurement precision and method complexity by using highly specific molecular probes and automated sequencing systems
Solution Approach 2:
The patent introduces molecular intermediaries (DNA/RNA probes, primers, and sequencing reagents) as mediators between the microbiota sample and the detection system. These intermediaries enable precise identification of bacterial species through hybridization and amplification reactions, achieving high measurement precision while using standardized laboratory protocols
2Reliability
If current treatments are used for CRS, then the treatment approach is conventional and simple, but the underlying microbiome imbalance is not addressed, leading to persistent inflammation
Solution Approach 1:
The patent implements a feedback-based treatment approach where microbiota composition is first characterized using culture-independent methods, then treatment is tailored based on the specific microbial imbalances identified. This feedback loop ensures that treatments directly address the underlying microbiome dysfunction, improving reliability by targeting the actual cause rather than just symptoms
Solution Approach 2:
The patent applies local quality by identifying specific bacterial species or groups that are depleted or overrepresented in individual CRS patients, then administering targeted probiotics or prebiotics to restore the specific microbial imbalance. This personalized approach ensures that each patient receives treatment tailored to their unique microbiota profile, thereby improving treatment effectiveness
Data Source
AI summary
Provided herein are compositions for improving sinus microbiota and treating sinusitis. Further provided are methods of detecting imbalance in the sinus microbiota that can be indicative of sinusitis, and methods of determining whether an individual has or is at risk of developing sinusitis, e.g., chronic sinusitis.